Guidelines for the rational clinical use of fentanyl transdermal patches （2026 revised edition）

doi:10.3760/cma.j.cn371439-20260625-00102

Abstract

Abstract:

In recent years， the clinical demand for fentanyl transdermal patches in the field of cancer pain has markedly increased. Nevertheless， prominent clinical problems persist， including inappropriate indication control， irregular dose titration and lagging management of adverse reactions. To address these issues， the Branch of Palliative Care， China International Exchange and Promotive Association for Medical and Health Care together with the Committee of Rehabilitation and Palliative Care， China Anti-Cancer Association organized a panel of specialists to revise the 2021 edition of Guidelines for the Rational Clinical Use of Fentanyl Transdermal Patches. Referring to the latest domestic and foreign literature and clinical research evidence， this guideline develops comprehensive and multi-dimensional recommendations covering core issues such as indication definition， preferred patient populations， dose conversion and titration， combination regimens for special types of cancer pain， adverse reaction intervention， drug interactions， safety management and patient education. This guideline intends to provide practical medication references for clinical practitioners， standardize the application of fentanyl transdermal patches in cancer pain management， and achieve the clinical goal of "standardized pain relief and comfortable anti-cancer treatment".

Key words: Cancer pain, Fentanyl transdermal patches, Diagnostic and treatment guideline, Rational drug use

Branch of Palliative Care， China International Exchange and Promotive Association for Medical and Health Care, Committee of Rehabilitation and Palliative Care， China Anti-Cancer Association. Guidelines for the rational clinical use of fentanyl transdermal patches （2026 revised edition）[J]. Journal of International Oncology, 2026, 53(11): 644-654.

Figures/Tables 6

References 48

[1]	Haroun R, Wood JN, Sikandar S. Mechanisms of cancer pain[J]. Front Pain Res (Lausanne), 2023, 3: 1030899. DOI: 10.3389/fpain.2022.1030899.
[2]	World Health Organization. Model list of essential medicines[DB/OL]. 2025. https://list.essentialmeds.org/.
[3]	国家卫生健康委员会. 国家基本药物目录(2026年版)[DB/OL]. 2026, https://www.nhc.gov.cn/yaozs/c100098/202607/0f4f2bdcfead449f8412453373522470/files/国家基本药物目录(2026年版).pdf.
[4]	Jobski K, Bantel C, Hoffmann F. Abuse, dependence and withdrawal associated with fentanyl and the role of its (designated) route of administration: an analysis of spontaneous reports from Europe[J]. Eur J Clin Pharmacol, 2023, 79(2): 257-267. DOI: 10.1007/s00228-022-03431-x.
[5]	Murray H, Gregoriou AN, Lepore A, et al. Why are US military personnel prescribed transdermal fentanyl patches[J]. BMJ Mil Health, 2023, 169(4): 335-339. DOI: 10.1136/bmjmilitary-2021-001894.
[6]	湖北省抗癌协会癌症康复与姑息治疗专业委员会. 芬太尼透皮贴剂临床合理用药指南[J]. 医药导报, 2021, 40(11): 1463-1474. DOI: 10.3870/j.issn.1004-0781.2021.11.001.
[7]	Mercadante S. An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain[J]. Expert Opin Pharmacother, 2024, 25(2): 171-179. DOI: 10.1080/14656566.2023.2200137.
[8]	Xu F, Qiu Z, Zhang M, et al. Transdermal drug delivery systems: a comprehensive review of mechanisms, technologies, and clinical applications[J]. Pharm Res, 2025, 42(12): 2429-2442. DOI: 10.1007/s11095-025-03962-9.
[9]	Wong WF, Ang KP, Sethi G, et al. Recent advancement of medical patch for transdermal drug delivery[J]. Medicina (Kaunas), 2023, 59(4): 778. DOI: 10.3390/medicina59040778.
[10]	Wei AD, Burgraff NJ, Oliveira LM, et al. Fentanyl blockade of K⁺ channels contributes to wooden chest syndrome[J]. J Physiol, 2026, 604(1): 582-604. DOI: 10.1113/JP289107.
[11]	Araldi D, Bonet IJM, Green PG, et al. Contribution of G-protein α-subunits to analgesia, hyperalgesia, and hyperalgesic priming induced by subanalgesic and analgesic doses of fentanyl and morphine[J]. J Neurosci, 2022, 42(7): 1196-1210. DOI: 10.1523/JNEUROSCI.1982-21.2021.
[12]	Kanamori T, Okada Y, Segawa H, et al. Agonistic activity of fentanyl analogs and their metabolites on opioid receptors[J]. Forensic Toxicol, 2022, 40(1): 156-162. DOI: 10.1007/s11419-021-00602-w. pmid: 36454497
[13]	Mizuno S, Takabayashi M, Makihara H, et al. Effect of changes in skin properties due to diabetes mellitus on the titration period of transdermal fentanyl: single-center retrospective study and diabetic animal model study[J]. J Pharm Health Care Sci, 2024, 10(1): 80. DOI: 10.1186/s40780-024-00402-5. pmid: 39696707
[14]	Skrzypczak H, Reed R, Brainard B, et al. The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses[J]. Equine Vet J, 2022, 54(1): 153-158. DOI: 10.1111/evj.13424.
[15]	Komatsu A, Miyano K, Nakayama D, et al. Novel opioid analgesics for the development of transdermal opioid patches that possess morphine-like pharmacological profiles rather than fentanyl: possible opioid switching alternatives among patch formula[J]. Anesth Analg, 2022, 134(5): 1082-1093. DOI: 10.1213/ANE.00000000 00005954. pmid: 35427270
[16]	于世英, 孙燕, 吴一龙, 等. 芬太尼透皮贴剂治疗4492例癌痛的临床疗效分析[J]. 中华肿瘤杂志, 2005, 27(6): 369-372. DOI: 10.3760/cma.j.issn.0253-3766.2005.06.014.
[17]	Hu X, Chen Y, Tang Y, et al. Developing a machine learning-based predictive model for the analgesic effectiveness of transdermal fentanyl in cancer patients: an interpretable approach[J]. Int J Clin Pharm, 2025, 47(4): 1011-1023. DOI: 10.1007/s11096-024-01860-5.
[18]	Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2018, 29(Suppl 4): iv166-iv191. DOI: 10.1093/annonc/mdy152.
[19]	Schlachter L, Stodtmann S, Voelkner A, et al. Population pharmacokinetics of atogepant for the prevention of migraine[J]. Clin Pharmacokinet, 2026, 65(1): 149-164. DOI: 10.1007/s40262-025-01566-5.
[20]	Li RJ, Caughey GE, Shakib S. Concomitant inpatient prescribing of strong opioids with sedatives: associations with comorbid conditions[J]. Pharmacol Res Perspect, 2021, 9(1): e00717. DOI: 10.1002/prp2.717.
[21]	Essmat N, Karádi DÁ, Zádor F, et al. Insights into the current and possible future use of opioid antagonists in relation to opioid-induced constipation and dysbiosis[J]. Molecules, 2023, 28(23): 7766. DOI: 10.3390/molecules28237766.
[22]	Agrawal MG, Kanungo H, Gupta M, et al. Transdermal patches for pain relief in orthodontic procedures: a narrative review[J]. Cureus, 2024, 16(1): e51669. DOI: 10.7759/cureus.51669.
[23]	Shkodra M, Caraceni A. Treatment of neuropathic pain directly due to cancer: an update[J]. Cancers (Basel), 2022, 14(8): 1992. DOI: 10.3390/cancers14081992.
[24]	中国临床肿瘤学会肿瘤支持与康复治疗专家委员会. 癌症相关神经病理性疼痛临床管理中国专家共识[J]. 国际肿瘤学杂志, 2026, 53(5): 257-267. DOI: 10.3760/cma.j.cn371439-20260118-00043.
[25]	Yang Y, Yang W, Zhang R, et al. Peripheral mechanism of cancer-induced bone pain[J]. Neurosci Bull, 2024, 40(6): 815-830. DOI: 10.1007/s12264-023-01126-6.
[26]	Almeida T, Monaco BA, Vasconcelos F, et al. Everything old is new again: revisiting hypophysectomy for the treatment of refractory cancer-related pain: a systematic review[J]. Neurosurg Rev, 2024, 47(1): 111. DOI: 10.1007/s10143-024-02347-7.
[27]	Knopp-Sihota JA, Newburn-Cook CV, Homik J, et al. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis[J]. Osteoporos Int, 2012, 23(1): 17-38. DOI: 10.1007/s00198-011-1676-0. pmid: 21660557
[28]	Ito A, Takeda M, Yoshimura T, et al. Anti-hyperalgesic effects of calcitonin on neuropathic pain interacting with its peripheral receptors[J]. Mol Pain, 2012, 8: 42. DOI: 10.1186/1744-8069-8-42. pmid: 22676202
[29]	中华人民共和国国家卫生健康委员会. 癌症疼痛诊疗规范(2018年版)[J]. 临床肿瘤学杂志, 2018, 23(10): 937-944. DOI: 10.19401/j.cnki.1007-3639.2017.04.012.
[30]	Kawana M, Miyasato A, Funato M, et al. Comparison of analgesic efficacy and safety of low-dose transdermal fentanyl and oral oxycodone in opioid-naïve patients with cancer pain[J]. Biol Pharm Bull, 2023, 46(10): 1444-1450. DOI: 10.1248/bpb.b23-00331. pmid: 37779046
[31]	Bahrami F, Rossi RM, De Nys K, et al. Implementing physics-based digital patient twins to tailor the switch of oral morphine to transdermal fentanyl patches based on patient physiology[J]. Eur J Pharm Sci, 2024, 195: 106727. DOI: 10.1016/j.ejps.2024.106727.
[32]	Yiu CH, Vitharana N, Gnjidic D, et al. Patient risk factors for opioid-related adverse drug events in hospitalized patients: a systematic review[J]. Pharmacotherapy, 2022, 42(3): 194-215. DOI: 10.1002/phar.2666.
[33]	Suzuki N, Okuyama M, Kamiya K. Effects and limitations of naldemedine for opioid-induced urinary retention: a case report[J]. J Palliat Med, 2023, 26(11): 1593-1595. DOI: 10.1089/jpm.2023.0269.
[34]	Sutaria N, Adawi W, Goldberg R, et al. Itch: pathogenesis and treatment[J]. J Am Acad Dermatol, 2022, 86(1): 17-34. DOI: 10.1016/j.jaad.2021.07.078.
[35]	Chiang YH, Lien CT, Su WH, et al. Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control[J]. BMC Palliat Care, 2024, 23(1): 150. DOI: 10.1186/s12904-024-01483-7.
[36]	Liu EY, Tamblyn R, Filion KB, et al. Concurrent prescriptions for opioids and benzodiazepines and risk of opioid overdose: protocol for a retrospective cohort study using linked administrative data[J]. BMJ Open, 2021, 11(2): e042299. DOI: 10.1136/bmjopen-2020-042299.
[37]	Sharma V, Simpson SH, Samanani S, et al. Concurrent use of opioids and benzodiazepines/Z-drugs in Alberta, Canada and the risk of hospitalisation and death: a case cross-over study[J]. BMJ Open, 2020, 10(11): e038692. DOI: 10.1136/bmjopen-2020-038692.
[38]	Cua A, Wickett E, Pesce AJ. Urinary metabolic ratio of pain manage-ment and substance abuse treatment drugs: drug-drug interactions[J]. J Opioid Manag, 2025, 21(7): 41-68. DOI: 10.5055/jom.0907.
[39]	Geist MJP, Ziesenitz VC, Bardenheuer HJ, et al. Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients[J]. Sci Rep, 2019, 9(1): 14635. DOI: 10.1038/s41598-019-51279-6. pmid: 31601999
[40]	Lewis R, Niazi-Ali S, McIvor A, et al. Triazole antifungal drug interactions-practical considerations for excellent prescribing[J]. J Antimicrob Chemother, 2024, 79(6): 1203-1217. DOI: 10.1093/jac/dkae103. pmid: 38629250
[41]	Nozari A, Akeju O, Mirzakhani H, et al. Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl[J]. J Pharm Pharmacol, 2019, 71(6): 982-987. DOI: 10.1111/jphp.13079. pmid: 30793320
[42]	Baneyx G, Parrott N, Meille C, et al. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration[J]. Eur J Pharm Sci, 2014, 56: 1-15. DOI: 10.1016/j.ejps.2014.02.002. pmid: 24530864
[43]	Baldo BA. Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity[J]. Arch Toxicol, 2021, 95(8): 2627-2642. DOI: 10.1007/s00204-021-03068-2. pmid: 33974096
[44]	Elli C, Novella A, Elli C, et al. Selective serotonin reuptake inhibitors and risk of serotonin syndrome as consequence of drug-drug interactions: analysis of the FDA Adverse Event Reporting System[J]. Med Princ Pract, 2025, 34(5): 456-463. DOI: 10.1159/000546109.
[45]	于世英, 孙燕, 张海春, 等. 芬太尼透皮贴剂治疗1664例老年癌痛的临床疗效分析[J]. 中华医学杂志, 2003, 83(22): 1931-1935. DOI: 10.3760/j:issn:0376-2491.2003.22.002.
[46]	Yamaguchi S, Uchida E, Terahara T, et al. Efficacy and safety of fentanyl citrate patch, including a low-dose 0.5 mg formulation, in opioid-naïve patients with cancer pain[J]. Clin Drug Investig, 2020, 40(11): 1041-1052. DOI: 10.1007/s40261-020-00965-9.
[47]	Ways TMM, Filippov SK, Maji S, et al. Mucus-penetrating nanoparticles based on chitosan grafted with various non-ionic polymers: synthesis, structural characterisation and diffusion studies[J]. J Colloid Interface Sci, 2022, 626: 251-264. DOI: 10.1016/j.jcis.2022.06.126.
[48]	Davis MP, Bohlke K, Davies A. Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline clinical insights[J]. J Pain Symptom Manage, 2026, 71(2): e141-e144. DOI: 10.1016/j.jpainsymman.2025.10.027.

证据特征			CSCO专家共识度
类别	水平	来源	CSCO专家共识度
1A	高	严谨的Meta分析、大型随机对照临床研究	一致共识（支持意见≥80%）
1B	高	严谨的Meta分析、大型随机对照临床研究	基本一致共识（支持意见60%~80%）
2A	稍低	一般质量的Meta分析、小型随机对照研究、设计良好的大型回顾性研究、病例-对照研究	一致共识（支持意见≥80%）
2B	稍低	一般质量的Meta分析、小型随机对照研究、设计良好的大型回顾性研究、病例-对照研究	基本一致共识（支持意见60%~80%）
3	低	非对照的单臂临床研究、病例报告、专家观点	无共识，且争议大（支持意见<60%）

推荐等级	标准
Ⅰ级推荐	1A类证据和部分2A类证据 CSCO指南将1A类证据，以及部分专家共识度高且在中国可及性好的2A类证据作为Ⅰ级推荐。具体为：适应证明确、可及性好、肿瘤治疗价值稳定，纳入《国家基本医疗保险、工伤保险和生育保险药品目录》的诊治措施
Ⅱ级推荐	1B类证据和部分2A类证据 CSCO指南将1B类证据，以及部分在中国可及性欠佳，但专家共识度较高的2A类证据作为Ⅱ级推荐。具体为：国内外随机对照研究，提供高级别证据，但可及性差或者效价比不高；对于临床获益明显但价格较贵的措施，考虑患者可能获益，也可以作为Ⅱ级推荐
Ⅲ级推荐	2B类证据和3类证据对于某些临床上习惯使用，或有探索价值的诊治措施，虽然循证医学证据相对不足，但专家组意见认为可以接受的，作为Ⅲ级推荐

阿片类药物	临床应用	在严重肝功能不全患者中给药方式的调整
芬太尼	较为安全	通常不需要调整剂量
吗啡	谨慎应用，监测患者神志	给药间隔时间延长为原来的2倍
羟考酮	谨慎应用，监测不良反应	起始剂量可调整为原来的1/2~2/3，随后滴定剂量可降低至原来的1/3
可待因	禁用

肾小球滤过率（ml/min）	剂量调整为原剂量的百分比
肾小球滤过率（ml/min）	芬太尼	吗啡	羟考酮	可待因
>50	100%	100%	100%	禁用
10~50	75%~100%	50%~75%	50%	禁用
<10	50%	25%~50%	禁用	禁用

药物	口服	非胃肠道	转换关系
吗啡	30 mg	10 mg	非胃肠道∶口服=1∶3
芬太尼透皮贴剂		25 μg/h	芬太尼透皮贴剂（μg/h，72 h）∶口服吗啡（mg/d）=1∶2
芬太尼透皮贴剂		25 μg/h	芬太尼透皮贴剂（μg/h，72 h）∶口服盐酸羟考酮（mg/d）=1∶1
芬太尼注射液			芬太尼透皮贴剂∶芬太尼注射液=1∶1